- Home
- MEGL vs RNAZ Comparison
MEGL vs RNAZ Comparison
Compare MEGL & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGL
- RNAZ
- Stock Information
- Founded
- MEGL 2016
- RNAZ 2016
- Country
- MEGL Hong Kong
- RNAZ United States
- Employees
- MEGL N/A
- RNAZ N/A
- Industry
- MEGL Finance: Consumer Services
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- MEGL Finance
- RNAZ Health Care
- Exchange
- MEGL Nasdaq
- RNAZ Nasdaq
- Market Cap
- MEGL 6.3M
- RNAZ 6.1M
- IPO Year
- MEGL 2022
- RNAZ 2021
- Fundamental
- Price
- MEGL $1.79
- RNAZ $11.74
- Analyst Decision
- MEGL
- RNAZ Strong Buy
- Analyst Count
- MEGL 0
- RNAZ 1
- Target Price
- MEGL N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- MEGL 134.8K
- RNAZ 239.7K
- Earning Date
- MEGL 08-05-2025
- RNAZ 08-13-2025
- Dividend Yield
- MEGL N/A
- RNAZ N/A
- EPS Growth
- MEGL N/A
- RNAZ N/A
- EPS
- MEGL N/A
- RNAZ N/A
- Revenue
- MEGL $1,645,862.00
- RNAZ N/A
- Revenue This Year
- MEGL N/A
- RNAZ N/A
- Revenue Next Year
- MEGL N/A
- RNAZ N/A
- P/E Ratio
- MEGL N/A
- RNAZ N/A
- Revenue Growth
- MEGL N/A
- RNAZ N/A
- 52 Week Low
- MEGL $1.02
- RNAZ $6.15
- 52 Week High
- MEGL $5.52
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- MEGL 63.62
- RNAZ 67.96
- Support Level
- MEGL $1.42
- RNAZ $9.02
- Resistance Level
- MEGL $2.27
- RNAZ $17.24
- Average True Range (ATR)
- MEGL 0.11
- RNAZ 1.28
- MACD
- MEGL 0.02
- RNAZ 0.31
- Stochastic Oscillator
- MEGL 43.53
- RNAZ 40.21
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.